ProfileGDS5678 / 1448738_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 45% 43% 43% 41% 42% 46% 44% 42% 41% 42% 43% 42% 43% 43% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 13.0831745
GSM967853U87-EV human glioblastoma xenograft - Control 22.9968343
GSM967854U87-EV human glioblastoma xenograft - Control 32.9989943
GSM967855U87-EV human glioblastoma xenograft - Control 42.8966241
GSM967856U87-EV human glioblastoma xenograft - Control 52.927642
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 13.158146
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 23.0873244
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 32.9703442
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 42.9345841
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 12.958542
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 22.9905343
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 32.9486342
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 43.0127943
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 52.9947443